<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002697</url>
  </required_header>
  <id_info>
    <org_study_id>95-072</org_study_id>
    <secondary_id>CDR0000064483</secondary_id>
    <secondary_id>NCI-V95-0784</secondary_id>
    <nct_id>NCT00002697</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>HIGH DOSE CHEMORADIOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR PATIENTS WITH PRIMARY REFRACTORY, RELAPSED AND POOR PROGNOSIS NON-HODGKIN'S LYMPHOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with radiation therapy and peripheral stem&#xD;
      cell transplantation may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of high-dose combination chemotherapy plus&#xD;
      radiation therapy followed by peripheral stem cell transplantation in patients with&#xD;
      refractory or recurrent non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of mobilization using filgrastim (G-CSF) with or without&#xD;
           standard-dose ifosfamide, carboplatin, and etoposide (ICE), conditioning using&#xD;
           ifosfamide and etoposide plus total body irradiation or high-dose ICE, and autologous&#xD;
           peripheral blood stem cell (PBSC) transplantation as salvage therapy in patients with&#xD;
           refractory, recurrent, or poor prognosis non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the efficacy of reinduction comprising ICE followed by autologous PBSC&#xD;
           transplantation in these patients.&#xD;
&#xD;
        -  Determine the ability of standard-dose ICE combined with hematopoietic growth factors to&#xD;
           mobilize PBSC in these patients.&#xD;
&#xD;
        -  Determine the contamination of PBSC by lymphoma cells in patients treated with this&#xD;
           mobilization regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease status (relapsed vs refractory),&#xD;
      lymphoma grade (low vs intermediate vs high), number of extranodal sites, serum lactic&#xD;
      dehydrogenase, performance status, age, and volume of disease.&#xD;
&#xD;
        -  Mobilization/harvest: Patients in first or greater complete remission (CR) are treated&#xD;
           on regimen A, whereas patients with recurrent or refractory disease are treated on&#xD;
           regimen B.&#xD;
&#xD;
             -  Regimen A: Patients with poor prognosis intermediate-grade lymphoma (IGL) in first&#xD;
                CR or IGL or low-grade lymphoma (LGL) in second or greater CR receive mobilization&#xD;
                with filgrastim (G-CSF) subcutaneously (SC) daily on days 1-7. Autologous&#xD;
                peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells on&#xD;
                days 5 and 6 (and day 7 if needed).&#xD;
&#xD;
             -  Regimen B: Patients who are currently on the MSKCC standard dose salvage therapy&#xD;
                protocol with ifosfamide, carboplatin, and etoposide (ICE) for recurrent or&#xD;
                refractory IGL receive additional mobilization with G-CSF after completion of the&#xD;
                last course of ICE. Patients with recurrent or refractory IGL, immunoblastic&#xD;
                lymphoma, or LGL who have not previously received ifosfamide and are not currently&#xD;
                on the MSKCC standard dose salvage protocol with ICE receive ifosfamide IV and&#xD;
                carboplatin on day 2 and etoposide IV on days 1-3 (standard-dose ICE) followed by&#xD;
                G-CSF SC. When blood counts recover, autologous PBSC are harvested and selected for&#xD;
                CD34+ cells.&#xD;
&#xD;
             -  Regimens A and B: If additional hematopoietic growth factors (HGFs) become&#xD;
                available, they may be administered concurrently with G-CSF. If inadequate CD34+&#xD;
                cells are collected, then autologous bone marrow is harvested.&#xD;
&#xD;
        -  Conditioning: Patients who are under age 60 and have not received dose-limiting&#xD;
           radiotherapy are treated on regimen C. Patients who are age 60 and over and patients who&#xD;
           are under age 60 and have received dose-limiting radiotherapy are treated on regimen D.&#xD;
&#xD;
             -  Regimen C: Patients undergo hyperfractionated total body irradiation twice a day on&#xD;
                days -10 to -7 and ifosfamide IV over 1 hour followed by etoposide IV over 23 hours&#xD;
                on days -6 to -2.&#xD;
&#xD;
             -  Regimen D: Patients receive ifosfamide IV over 1 hour, followed by etoposide IV&#xD;
                over 11 hours, followed by carboplatin IV over 1 hour, followed by etoposide IV&#xD;
                over 11 hours on days -7 to -3 (high-dose ICE).&#xD;
&#xD;
             -  Regimens C and D: Patients with residual or relapsed disease may undergo boost&#xD;
                radiotherapy twice a day, 5 days a week, for 1-2 weeks before conditioning or after&#xD;
                transplantation.&#xD;
&#xD;
        -  Transplantation: PBSC or bone marrow is reinfused on day 0. Patients receive G-CSF SC&#xD;
           every 12 hours beginning on day 1 and continuing until blood counts recover. If&#xD;
           additional HGFs become available, they may be administered concurrently with G-CSF.&#xD;
&#xD;
      Quality of life is assessed at baseline and then at 6, 12, and 24 months after&#xD;
      transplantation.&#xD;
&#xD;
      Patients are followed at 1 and 3 months, every 3 months through year 2, every 4 months&#xD;
      through year 5, and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (20 for regimen A and 60 for regimen B) will be&#xD;
      accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1995</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Histologically proven recurrent non-Hodgkin's lymphoma&#xD;
&#xD;
                    -  Previously in complete remission (CR)&#xD;
&#xD;
               -  Refractory or recurrent intermediate-grade lymphoma (IGL) or high-grade&#xD;
                  immunoblastic lymphoma (IBL) meeting 1 of the following conditions:&#xD;
&#xD;
                    -  In partial remission (PR) or CR to and currently enrolled on the MSKCC&#xD;
                       standard dose salvage regimen with ifosfamide, carboplatin, and etoposide&#xD;
                       (ICE)&#xD;
&#xD;
                    -  In PR or CR after 1-2 other salvage chemotherapy regimens (e.g., 3 courses&#xD;
                       of dexamethasone, high-dose cytarabine, and cisplatin (DHAP); 2 courses of&#xD;
                       cyclophosphamide, mechlorethamine, vincristine, procarbazine, and prednisone&#xD;
                       (C-MOPP))&#xD;
&#xD;
                         -  No prior ifosfamide&#xD;
&#xD;
               -  Low-grade lymphoma&#xD;
&#xD;
                    -  In second or greater remission or chemosensitive relapse&#xD;
&#xD;
                    -  No HLA identical sibling donor available&#xD;
&#xD;
               -  IGL or IBL&#xD;
&#xD;
                    -  In first CR&#xD;
&#xD;
                    -  Poor prognosis, defined by age-adjusted international index of 3 or 4 based&#xD;
                       on lactic dehydrogenase, number of extranodal sites, stage, and performance&#xD;
                       status&#xD;
&#xD;
          -  Adequate bone marrow cellularity&#xD;
&#xD;
          -  No lymphoblastic or small noncleaved cell lymphoma&#xD;
&#xD;
          -  Ineligible for total body irradiation (TBI) phase of study if prior radiotherapy dose&#xD;
             precludes the use of TBI NOTE: A new classification scheme for adult non-Hodgkin's&#xD;
             lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot;&#xD;
             lymphoma will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade&#xD;
             lymphoma.However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Physiologic 18 to 65&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (if no history of Gilbert's disease)&#xD;
&#xD;
          -  No chronic active or persistent hepatitis&#xD;
&#xD;
          -  Hepatitis B positivity allowed provided that the following conditions are met:&#xD;
&#xD;
               -  Bilirubin same as above*&#xD;
&#xD;
               -  SGPT no greater than 500 IU/L*&#xD;
&#xD;
               -  Alkaline phosphatase no greater than 2 times normal* NOTE: * In the absence of&#xD;
                  liver involvement by lymphoma&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No history of chronic renal insufficiency&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 50% by echocardiogram or MUGA scan&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No arrhythmia other than chronic atrial fibrillation&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 50% predicted (corrected for hemoglobin and alveolar ventilation)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Moskowitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

